Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.
6 Dec 2023 | |
Written by Anna Lakey | |
Community news |
Clinicians |
The Mark Foundation for Cancer Research ASPIRE program covers research, often high-risk and at early stages, into multiple types of adult and pediatric cancers, encompassing both solid tumors and blood cancers. Projects typically start as an ASPIRE I; those that successfully demonstrate feasibility or proof of concept may be invited to apply for an ASPIRE II to further develop and expand the research, as in Charlie's case.
With this ASPIRE II award, Charlie will team up with Sherene Loi to expand upon his previous ASPIRE award research, "Environmental EXPosures and Normal tissue Somatic Evolution (EXPANSE)". This work contributed to a growing body of evidence suggesting that many cancer risk factors and environmental carcinogens alter tissue microenvironments and the properties of pre-existing mutant cells to allow for cancer initiation without directly causing mutations, in a process termed “tumor promotion”.
The new project will delve deeper into the mechanisms by which various risk and protective factors modulate the fate of tumor-initiating cells through non-mutagenic pathways. In addition to continuing the work on pollutants and lung cancer, they will investigate the well-documented but poorly understood protective effect of pregnancies and breastfeeding against breast cancer incidence.
"We are very excited to continue our work with the Mark Foundation to understand how air pollution and tumour promoters contribute to initiating lung cancer in an effort to find inflammatory mechanisms that can be attenuated to arrest cancer development." Charlie Swanton
The project has been awarded US$755,020.
Congratulations to both!